E2 ModeratePreliminaryPEM ?Case-ControlPeer-reviewedMachine draft
Extracellular Vesicle Protein and MiRNA Signatures as Biomarkers for Post-Infectious ME/CFS Patients.
Seifert, Martina, Schäfers, Johannes, Douglas, Fiona F et al. · International journal of molecular sciences · 2026 · DOI
Quick Summary
Researchers examined tiny packages of proteins and molecules (called extracellular vesicles) found in the blood of ME/CFS patients to see if they contain unique signatures that could help diagnose the disease. They found that certain proteins and a specific small molecule called hsa-let-7b-5p were different in ME/CFS patients compared to healthy people, and these differences were linked to worse fatigue, pain, and immune problems. This discovery suggests that blood tests measuring these substances could eventually help doctors diagnose ME/CFS and better understand who has the disease.
Why It Matters
ME/CFS currently lacks objective diagnostic tests, making early recognition and confirmation difficult for patients. This research identifies candidate biomarkers in blood that could enable development of diagnostic tests and help researchers understand disease mechanisms. If validated in larger studies, these findings could transform ME/CFS diagnosis from subjective clinical criteria to objective laboratory measurements.
Observed Findings
- Hemoglobin subunit alpha and insulin-like growth factor-binding protein acid labile subunit were altered in extracellular vesicles from ME/CFS patients compared to healthy controls.
- Hsa-let-7b-5p was significantly downregulated in EVs from post-COVID-19 ME/CFS patients (n=12) versus healthy controls (n=15).
- Reduced hsa-let-7b-5p expression correlated with impaired physical functioning and increased fatigue, pain, and immune activation markers.
Inferred Conclusions
- Extracellular vesicle cargo differences, particularly hemoglobin subunit alpha, IGFALS, and hsa-let-7b-5p, represent promising candidate biomarkers for ME/CFS diagnosis and patient stratification.
- Hsa-let-7b-5p downregulation may reflect or contribute to the symptom burden and immune dysregulation characteristic of post-COVID-19 ME/CFS.
Remaining Questions
- Do these biomarkers distinguish ME/CFS from other post-infectious illnesses, autoimmune diseases, or other chronic fatigue conditions?
- Are these molecular changes present in ME/CFS patients with non-COVID-19 infectious origins, or are they specific to post-COVID-19 ME/CFS?
- What is the mechanistic relationship between reduced hsa-let-7b-5p and fatigue, pain, and immune activation—is it cause or consequence?
- Can these biomarkers be validated in larger, independent cohorts that include male patients and diverse geographic populations?
What This Study Does Not Prove
This study does not prove that these molecular changes cause ME/CFS or that they are specific to ME/CFS—only that they differ from healthy controls in this small group. The small sample size means findings must be replicated in larger, independent cohorts before clinical use. The study also does not establish whether these markers can distinguish ME/CFS from other post-infectious illnesses or chronic conditions.
Tags
Symptom:Post-Exertional MalaisePainFatigue
Biomarker:Gene ExpressionBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:PEM Not DefinedSmall SampleExploratory OnlyMixed Cohort
Metadata
- DOI
- 10.3390/ijms27052314
- PMID
- 41828537
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026